Quality of life related to recombinant TSH treatment compared to no treatment related to iodine uptake, in patient with thyroid cancer.A double blinded, randomized crossover study.Dathyrca I
- Conditions
- in patients with thyroid cancer (follicular or papillary), injektion with recombinant TSH to increase s-TSH before iodine uptake to detect remaining cancer og recurrence of cancer in patients surgecal treated thyroid cancerMedDRA version: 9.1Level: LLTClassification code 10033701Term: Papillary thyroid cancerMedDRA version: 9.1Level: LLTClassification code 10016935Term: Follicular thyroid cancer
- Registration Number
- EUCTR2007-002713-39-DK
- Lead Sponsor
- dept of endocrinology J 106, herlev Hosptial
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients, surgery treated for thyroid cancer, follicular og papillary.
age 18-75yaer
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
<18 year old
>75 year old
pregnant or lactating women
persons not able to give informed consent
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Quality of life related to recombinant TSH treatment compared to <br>no treatment related to iodine uptake, in patient with thyroid cancer (follikcular, papillary).<br>A double blinded, randomized crossover study.<br>;Secondary Objective: ;Primary end point(s): quality of life evaluated with VAS, SF- 36, Eorts QLC 30
- Secondary Outcome Measures
Name Time Method